Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$15.30 USD
-0.38 (-2.42%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $15.32 +0.02 (0.13%) 4:48 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Earnings News For URGN
-
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
-
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
-
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
-
UroGen Pharma Reports Third Quarter 2023 Financial Results
-
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
-
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
-
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates
-
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
-
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline
-
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
-
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
-
Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates
-
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
-
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
-
Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates
-
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
-
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
-
Urogen Pharma (URGN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
UROGEN PHARMA (URGN) Reports Q2 Loss, Tops Revenue Estimates
-
UROGEN PHARMA (URGN) Reports Q1 Loss, Misses Revenue Estimates
-
UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates